FDA Approves the First Heart Valve Designed to Grow With Children

The FDA has approved the Autus Size-Adjustable Valve, the first replacement heart valve designed to be enlarged as a child grows. Approved on October 1, 2026, it is intended for young children with congenital disease of the pulmonary valve, and could reduce the number of open-heart operations these children face before adulthood.

The problem it solves

About 4,200 babies are born in the US each year with abnormalities of the pulmonary valve, which controls blood flow from the heart to the lungs. The valve may be narrowed (stenosis) or fail to form an opening at all (atresia). Many of these children need the valve replaced. The difficulty is that an artificial valve is a fixed size, and a child is not. A valve that fits a two-year-old is far too small for a teenager, so children have traditionally needed multiple open-heart surgeries to swap in larger valves as they grow. Valves made from animal tissue also tend to deteriorate faster in children than in adults.

How the Autus valve works

The Autus valve is implanted surgically at a diameter of about 13 millimeters, suitable for a toddler or preschool-aged child. As the child grows, a cardiologist can thread a small balloon catheter through a blood vessel to the valve and inflate it, stretching the valve’s frame to a larger size — without opening the chest. It can be expanded in stages up to 22 millimeters, an adult size. Its leaflets, the flaps that open and close with each heartbeat, are made from a synthetic polymer rather than animal tissue.

The evidence

The approval is based on a study of 62 children at 12 US sites. All implant procedures were successful. Among the first 60 patients followed for six months, the valves performed acceptably, with no deaths, blood clots or strokes. Two children outgrew their valve during the study, and in both the valve was successfully expanded without surgery — the central test of the concept.

What went wrong, and what is unknown

The study was not without problems. There were three fractures of the valve frame and two cases of reduced leaflet movement, none of which caused symptoms. More fundamentally, six months of follow-up cannot show how the valve performs over the 10 to 15 years it would need to last to carry a child to adulthood, how many expansions each child will need, or how long the polymer leaflets will hold up. Longer-term data will be essential.

What it could mean for families

Each open-heart surgery carries risk, a hospital stay, weeks of recovery, and scar tissue that makes the next operation harder. For families, it can also mean years of anxiety between operations. A valve that can be widened through a catheter procedure, typically requiring a much shorter hospital stay, could spare a child several of those surgeries. As FDA device chief Michelle Tarver noted, the timing of valve replacement in children with congenital heart disease has always been a difficult decision — operate too early and the child outgrows the valve sooner; wait too long and the heart can be damaged.

Life with a congenital heart defect

Thanks to advances in surgery, the great majority of children born with heart defects now survive into adulthood, and there are more adults than children living with congenital heart disease in the US. That success has shifted attention from survival to quality of life: fewer operations, less time in hospital, and more normal childhoods. Many of these patients will need heart procedures throughout their lives, so every open-heart surgery avoided in childhood matters. A valve that reaches adult size also opens the door, later on, to replacing it through a catheter rather than surgery, as is now common in adults.

How it was approved

The valve, developed by Autus Valve Technologies, received Breakthrough Device designation and was approved through the FDA’s most rigorous device pathway, premarket approval. It is also the first pediatric device approved through the agency’s Total Product Life Cycle Advisory Program (TAP), which gives developers early and frequent access to FDA feedback. Devices for children are often neglected because the market is small; programs like this are intended to change that.

The bigger picture in pediatric devices

Most medical devices are designed for adults and adapted, often awkwardly, for children. A valve built around growth from the start reflects a different approach, and other groups are pursuing related ideas, from valves made of a child’s own cells to ones that remodel with the body. The Autus valve is the first to reach approval.

What comes next

The valve applies to the pulmonary position only; other valves, such as the aortic and mitral, face higher pressures and are harder problems. Surgeons and cardiologists will be watching longer follow-up from the trial and real-world experience as the device is rolled out at pediatric heart centers. Families considering it should discuss with their child’s cardiac team whether it suits their child’s anatomy and condition. This is regulatory news, not medical advice.